BioSpace BioPharm Exec
Wednesday, January 29, 2014
Facebook  |  Linked In  |  Twitter  |  RSS  |  Subscribe

Will 2014 Be The Year For RNA Companies?

January 29, 2014

By Karl Thiel for BioSpace.com

It's been a remarkable month...and a remarkable year...for RNA. Companies focused on manipulating RNA messages—by RNA interference (RNAi), antisense, or other techniques—have been white hot in an already sizzling biotech sector.

The Nasdaq Biotechnology Index is up nearly 75 percent since the beginning of 2013. But, look at RNA companies like Alnylam over the same period (up 340 percent), or Isis Pharmaceuticals (up 355 percent). Even small, early stage companies like More...

More By Karl Thiel

This was the month of big surprises—as in, clinical results that caught the market off-guard and sent the stocks of companies soaring. I mentioned Sarepta in the introduction, but both ArQule and Intercept found big success with liver drugs-—with Intercept's stock more than quintupling in the course of two trading sessions after the company's treatment for nonalcoholic steatohepatitis worked so well the clinical trial was halted. The company's market cap shot up to over $8 billion before it came back down to earth.

Aduro Biotech, meanwhile, got unexpectedly strong results right next door at the pancreas. Aduro isn't public, but it made a splash by showing that a combination of two cancer vaccines—each pretty much abandoned after failing individually—could do impressive things in combination, significantly extending survival in a mid-stage study of patients with pancreatic cancer, a very tough illness indeed. It's a great reminder that combinations and cocktails can make a big contribution to progress. And if Aduro is successful, it will be a great story—they paid next to nothing for these assets. -KT
ArQule, Inc. (ARQL) Soars As FDA Panel Favors Continuation Of Liver Cancer Drug Study, Stock Up +6.78% At Market Close (January 17, 2014)
More...

Sarepta (SRPT) Surges Following Results Of Phase 2b Eteplirsen Therapy
More...

As Big Biotech Talks Cancer Vaccines, Bay Area's Aduro Biotech Nails Mid-Stage Pancreatic CA Study
More...

Intercept Pharma (ICPT) Falls As CEO Says It May Need Help Big Pharma's Help
More...

Neurocrine (NBIX) Rockets On Positive Ph2 Movement Disorder Drug Data; Stock Up +75.56% At Market Close (January 7, 2014)
More...


More Bench To Clinic News
Biotech is a young industry, but it's been around long enough to create some seasoned veterans who choose to enjoy the fruits of their labor in retirement. Gilead Sciences' head of commercial operations, Kevin Young, is stepping down, after a 10-year stint at the company that saw a 9-fold increase in revenues. The aptly named Young is only 56, however, and will stay with the company in an advisory role. Amgen CFO Jonathan Peacock, meanwhile, is leaving to pursue "broader career opportunities." Exactly what that means and how he will add breadth to an already successful career is not yet clear, but the LA Times reports that he hasn't yet accepted a position elsewhere.

Meanwhile, troubled Teva Pharmaceuticals gets a new CEO effective February 11. Erez Vigodman will fill a seat left empty since Jeremy Levin's ouster last October. Vigodman is current chief executive at Makhteshim Agan Industries, a leading generic agrochemical company, and is considered a turnaround specialist. And Incyte landed the president of Novartis Oncology as its new CEO. Herve Hoppenot will be leaving behind one of the more envied oncology pipelines in the industry. -KT
Novartis (NVS) Head, Herve Hoppenot, Flys The Coop To Become CEO Of Incyte (INCY)
More...

Lexicon Pharma (LXRX) Axes 45 Percent Of Jobs, CEO To Step Down
More...

First Gilead (GILD), Now Amgen (AMGN) Loses A Top Exec
More...

Teva (TEVA) Confirms Rumor, Picks Turnaround Specialist As New CEO
More...

Gilead (GILD)'s Head Of Commercial Operations To Step Down
More...


More Career Track News
I mentioned a number of RNA-focused deals from the past month in the introduction...but wait, there's more! Santaris Pharma inked a deal with Roche covering its "locked nucleic acid" technology, which targets mRNA and microRNA. Santaris says its platform overcomes limitations of other RNA-targeting technologies like siRNA and antisense due to the small size of their molecules and their high binding affinity. According to the company, they can work in a variety of tissues without special delivery vehicles. Roche was intrigued enough to pay $10 million upfront and a further $138 million in potential milestones, plus research funding.

Sangamo BioSciences is earning $20 million upfront—and up to $300 million more, plus double-digit royalties and a co-promotion option—under a co-development agreement with Biogen Idec aimed at a potentially curative approach to sickle cell disease and beta-thalassemia. This of course, involves Sangamo's very cool-sounding zinc finger technology. -KT
Nantbioscience Scores $75M CA Deal With Celgene Corporation (CELG)
More...

Regeneron (REGN), Bayer HealthCare (BAY) Forge Pact Worth $65M+ To Co-develop Wet AMD Drug
More...

Jazz (JAZZ) Forges Pact Worth $397M For Aerial BioPharma's Sleepiness Drug
More...

Santaris, Roche (RHHBY) Strike $148M+ Alliance To Design And Develop RNA-Targeted Drugs
More...

Biogen (BIIB) May Pay Sangamo BioSciences, Inc. (SGMO) As Much As $320M For Blood Drugs; SGMA Soars +38.32% At Market Close (January 9, 2014)
More...


More Golden Handshakes News

Top Jobs
• BioTechxus (Houston, Texas)

America Stem Cell
Chief Medical Officer
Reporting to the CEO, the CMO will lead the company in developing and commercializing our main product. The CMO will participate in developing and executing on current and long-range strategies. CMO will provide the leadership, management and vision necessary for leading edge development.

• Pharm Country (Norwalk, Connecticut)

Robert Half Executive Search
Chief Financial Officer
Will report directly to the CEO and will work closely with the executive management team and the Company's Board of Directors. In this role, the CFO will be an advisor to and collaborator with the CEO and the leadership team in providing critical insights to the strategy.

• Biotech Bay (San Francisco, California)

Avalanche Biotech
Chief Financial Officer
Seeking an experienced CFO who will be responsible for the oversight of financial operations and key member of the executive management team. In this role, you will work in a fast-paced environment to take an active financial leadership role with our team.

• Southern Pharm (Boca Raton, Florida)

Biotest Pharmaceuticals
Vice President, Supply Chain
Responsible for optimizing the procurement and management of material (raw materials and finished goods) in a cost/quality/delivery/service effective manner. This role sets and leads strategies related to the Sourcing, Purchasing, Logistics, Warehousing, Demand/Inventory Management and Supplier Quality.

Get Noticed! Add your resume to the BioSpace Career Center!
See more than 5,000 job postings in the BioSpace Career Center!

Juno Therapeutics has quite a storied history, and it's brand new company. Having now raised over $145 million in a Series A round (yes, that's Series A), Juno attracted investments not just from A-list VCs but also Amazon.com's Jeff Bezos. The company's cancer vaccine programs have produced some very promising looking results, but it has also spawned a legal dispute. Juno took a license to chimeric antigen receptor technology from St. Jude Children's Research Hospital, which is now in a dispute with the University of Pennsylvania and its licensee Novartis. With Juno saying it will pay 80% of the legal expenses, it sees the stakes as being fairly high. Luckily, it's flushed with cash.

Glycomimetics, meanwhile, becomes the first biotech IPO of 2014, while Alkermes fills up its coffers with a PIPE offering (private investment in public entity) to Invesco. That gives the company quite a warchest as it looks to bring a long-acting version of the antipsychotic Abilify to market next year. -KT
Already-Rich Startup, Juno Therapeutics, Expands Series A Funding Round To $145M
More...

Sanofi (SAN.PA) Pays $700M For 12 Percent Of Alnylam (ALNY)
More...

Alkermes (ALKS) Hauls In $250M It Doesn't Need, But It May Prevent It From Being Swallowed Up
More...

GlycoMimetics (GLYC) Finally Prices Upraised IPO At $8 Per Share
More...

Amgen (AMGN)'s Bay Area Spinoff, Atara Biotherapeutics, Hauls In $52M Series B Financing
More...


More Money Talk News

Actavis CEO Paul Bisaro told the crowd at the JP Morgan Healthcare Conference something they already knew: that China does not have a business-friendly climate, especially for Western companies. But more surprising was his conclusion, that the massive potential market China represents just isn't worth the hassle. As a leading generic manufacturer, Actavis has a lot to gain in China, but the company is in the process of pulling out of the country. That raises the question of whether other companies might eventually follow suit, but it should be pointed out that Actavis hadn't made massive investments in the region, so withdrawing is a relatively modest affair. -KT
Actavis (ACT) To Exit China As Unfriendly Government Not Worth It
More...

Gentium Shareholders Sue Over $1B Jazz (JAZZ) Deal
More...

Doc Admits He Leaked Secret ALZ's Trial Information To "Friend" At SAC
More...

Teva (TEVA) Asks Supreme Court To Review Copaxone Ruling
More...

Whistleblower Lawsuit Costs Genzyme (GENZ) $22M
More...


More Legal Briefs News
Johnson & Johnson and partner Bayer have been hoping to expand the use of Xarelto to patients with acute coronary syndrome, but narrowly failed to convince an FDA advisory panel back in 2012. Their second attempt to address the concerns previously raised again, failed to sway the panel this time by unanimous vote (with one abstention). But another blood-thinner, Merck's Vorapaxar, did get a positive vote. Assuming it is eventually approved, the first-in-class drug will likely be engaged in an epic, high-stakes battle with Xarelto, which is on track to top $1 billion in sales this year.

AstraZeneca and Bristol-Myers Squibb's Farxiga (dapagliflozin), meanwhile, becomes the first new chemical entity approved in 2014. This diabetes drug is soon to be AstraZeneca's alone, as the company will complete its acquisition of BMS' interest in their diabetes alliance sometime this quarter. -KT
FDA Panel Once Again Rejects Wider Use Of J&J (JNJ) Drug
More...

Merck (MRK)'s Blood Thinner, Vorapaxar, Gets "Yes" Vote From FDA Panel
More...

Astra (AZN), Bristol (BMY)'s New Approach Diabetes Drug, Farxiga™, Wins FDA Approval
More...

United Therapeutics (UTHR) Hits All-Time High As FDA OKs Lung Disease Drug; Stock Up +30.36% At Market Close (Dec. 23, 2013)
More...

Glaxo (GSK)'s Malaria Drug Wins FDA "Breakthrough" Status
More...


More Rockville Files News

Karl Thiel is an analyst for The Motley Fool and a longtime follower of the biotech industry. He lives in Austin, Texas.

You may contact Karl Thiel at Karl.thiel@biospace.com.

BioSpace, Inc.
6465 South Greenwood Plaza, Suite 400
Centennial, Colorado 80111 U.S.A.
Phone: 877-277-7585
Fax: 800-595-2929
BioSpace, Inc.
90 New Montgomery Street, Suite 414
San Francisco, California 94105 U.S.A.
Phone: 877-277-7585
Fax: 415-576-9217



If someone forwarded this news to you and you'd like to receive your own complimentary monthly copy, simply Subscribe here.

Safely unsubscribe from Biospace.com e-mail at any time by managing your account here.
BioSpace in an onTargetjobs company